Gauzy Ltd. Receives Nasdaq Deficiency Notice for Board Independence, Faces Delisting Risk

summarizeSummary

Gauzy Ltd. received a Nasdaq deficiency letter due to non-compliance with board independence rules, a direct result of recent director resignations, and now has 45 days to regain compliance or face potential delisting.

check_boxKey Events

• Nasdaq Deficiency Letter Received

  Gauzy Ltd. was notified by Nasdaq on February 3, 2026, of non-compliance with board and committee independence rules (Nasdaq Listing Rules 5605(b)(1), 5605(c)(2), and 5605(d)(2)).

• Result of Recent Resignations

  The deficiency stems from the recent resignations of two board members, leaving the board composed entirely of non-independent directors. This follows the 6-K filed on January 27, 2026, which disclosed these resignations.

• 45-Day Compliance Deadline

  The company has 45 calendar days, until March 20, 2026, to appoint sufficient independent directors or submit a plan to regain compliance.

• Potential Delisting

  Failure to comply could lead to delisting from Nasdaq, though the company has the right to appeal.

auto_awesomeAnalysis

This 6-K filing confirms the formal notification from Nasdaq regarding Gauzy's non-compliance with board and committee independence requirements, following the previously disclosed resignations of two board members on January 27, 2026. The company's board is now composed solely of non-independent directors, triggering a serious listing deficiency. Gauzy has a critical 45-day window to appoint new independent directors or submit a compliance plan, with potential delisting if it fails to resolve the issue. For a micro-cap company, maintaining Nasdaq listing is crucial for liquidity and investor confidence, making this a significant risk factor.